



COMPANY OVERVIEW

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing REL-1017 (dextromethadone) in multiple indications. RELM-1017 is in Phase 2 for treatment resistant depression and preclinical testing for additional indications. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.

MANAGEMENT TEAM

Sergio Traversa
Chief Executive Officer and Interim
Chief Financial Officer

Dr. Ottavio Vitolo
Senior Vice President, Head of R&D and
Chief Medical Officer

RECENT NEWS

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017

Dec 12 2018, 8:00 AM EST

RELMADA THERAPEUTICS, INC.

750 Third Avenue
9th Floor
New York, NY 10017
US

STOCK OVERVIEW

Symbol	RLMD
Exchange	OTCQB
Market Cap	32.97m
Last Price	\$1.16
52-Week Range	\$0.61 - \$1.94

12/14/2018 03:11 PM EST

INVESTOR RELATIONS

Relmada Therapeutics, Inc.
Michael Bell
750 Third Avenue
9th Floor
New York, NY 10017
T: 212-848-9401
mbell@relmada.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.